Skip to main content

Table 2 Association between 10-year CVD risk and i) initiations or ii) discontinuations of ABC in the pre- and post-March 2008 periods (factors included in adjusted analyses are listed in the Methods section)

From: Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration

Framingham risk group

ABC initiations/total ART initiations

Percentage (95 % CI)

aOR (95 % CI)

i) Initiations of ABC

 Pre-March 2008

  Low/unknown

1,251/9,213

13.6 (12.8, 14.3)

1

  Moderate/high

111/648

17.1 (13.9, 20.3)

1.14 (0.90, 1.44)

 Post-March 2008

  Low/unknown

326/4,282

7.6 (6.8, 8.4)

1

  Moderate/high

33/622

5.3 (3.5, 7.1)

0.74 (0.48, 1.13)

  Interaction P value

  

0.007

ii) Discontinuations of ABC

Discontinuations/PYRS

Rate/100 PYRS (95 % CI)

aRR (95 % CI)

Suppressed/low viral load

 Pre-March 2008

  Low/unknown

2,045/16,506

12.4 (11.9, 12.9)

1

  Moderate/high

562/5,465

10.3 (9.4, 11.1)

1.04 (0.93, 1.16)

 Post-March 2008

  Low/unknown

1,403/13,950

10.1 (9.5, 10.6)

1

  Moderate/high

880/6,560

13.4 (12.5, 14.3)

1.49 (1.34, 1.65)

  Interaction P value

  

0.0001

Non-suppressed viral load

 Pre-March 2008

  Low/unknown

2,966/7,766

38.2 (36.8, 39.6)

1

  Moderate/high

662/2,041

32.4 (29.9, 34.9)

0.99 (0.90, 1.09)

 Post-March 2008

  Low/unknown

622/2,297

27.1 (25.0, 29.2)

1

  Moderate/high

236/921

25.6 (22.4, 28.9)

1.23 (1.02, 1.48)

  Interaction P value

  

0.07

  1. ABC abacavir, aOR adjusted odds ratio, aRR adjusted rate ratio, ART antiretroviral therapy, CI confidence interval, CVD cardiovascular disease, PYRS person-years